This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Are Options Traders Betting on a Big Move in Axovant Sciences (AXON) Stock?
by Zacks Equity Research
Investors need to pay close attention to Axovant Sciences (AXON) stock based on the movements in the options market lately.
Options Traders Expect Huge Moves in Axovant Sciences (AXON) Stock
by Zacks Equity Research
Investors in Axovant Sciences (AXON) need to pay close attention to the stock based on moves in the options market lately.
3 Gene Therapy Stocks Investors Can Bet on in Rest of 2018
by Ekta Bagri
Gene therapy continues to be in focus with the recent spate of deals and acquisitions. We highlight three stocks, which have promising candidates in their pipeline.
Biotech Stock Roundup: BIIB's Gain on Alzheimer's Data, Regulatory Updates & More
by Zacks Equity Research
Biogen's results from a phase II study in the much-pursued Alzheimer's disease was all over the biotech sector last week.
Axovant, Benitec Gain on Licensing Deal for Gene Therapy
by Zacks Equity Research
Axovant Sciences' (AXON) shares gain, following the news of a licensing deal for oculopharyngeal muscular dystrophy candidate with Benitec Biopharma.
Solid (SLDB) Surges as FDA Lifts Clinical Hold on DMD Drug
by Zacks Equity Research
Solid Biosciences' (SLDB) shares gained significantly after the FDA lifted the clinical hold on its phase I/II trial for its lead candidate, SGT-001 for DMD.
Top Ranked Momentum Stocks to Buy for June 12th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 12th:
Implied Volatility Surging for Axovant (AXON) Stock Options
by Zacks Equity Research
Axovant (AXON) needs investors to pay close attention to the stock based on moves in the options market lately.
Acorda Therapeutics (ACOR) in Focus: Stock Moves 8.9% Higher
by Zacks Equity Research
Acorda Therapeutics (ACOR) was a big mover last session, as the company saw its shares rise nearly 9% on the day.
Axovant Sciences (AXON) Soars: Stock Adds 5.5% in Session
by Zacks Equity Research
Axovant Sciences (AXON) shares rose nearly 6% in the last trading session, amid huge volumes.
Axovant (AXON) Gains on Licensing Deal with Oxford BioMedica
by Zacks Equity Research
Axovant Sciences' (AXON) shares rally, following news of a licensing deal for AXO-LentiPD from Oxford BioMedica for Parkinson's disease.
Options Traders Expect Huge Moves in Axovant Sciences (AXON) Stock
by Zacks Equity Research
Surging implied volatility makes Axovant Sciences (AXON) stock lucrative to the option traders.
Implied Volatility Surging for Axovant Sciences (AXON) Stock Options
by Zacks Equity Research
Surging implied volatility makes Axovant Sciences (AXON) stock lucrative to the option traders.
Are Options Traders Betting on a Big Move in Axovant Sciences (AXON) Stock?
by Zacks Equity Research
Surging implied volatility makes Axovant Sciences (AXON) stock lucrative to the option traders.
Keryx Biopharmaceuticals (KERX) in Focus: Stock Moves 10.8% Higher
by Zacks Equity Research
Keryx Biopharmaceuticals (KERX) was a big mover last session, as the company saw its shares nearly 11% on the day amid huge volumes.
Exact Sciences (EXAS) Looks Good: Stock Adds 9.8% in Session
by Zacks Equity Research
Exact Sciences (EXAS) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Geron (GERN) in Focus: Stock Moves 9.2% Higher
by Zacks Equity Research
Geron (GERN) saw its shares rise over 9% on the day after the company received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its experimental blood-cancer medicine, imetelstat.
Alkermes (ALKS) in Focus: Stock Moves 11.1% Higher
by Zacks Equity Research
Alkermes plc (ALKS) saw its shares rise over 11% on the day.
Envision Healthcare (EVHC) Looks Good: Stock Adds 10.9% in Session
by Zacks Equity Research
Envision Healthcare (EVHC) was a big mover last session, as the company saw its shares rise almost 11% on the day amid huge volumes.
Abeona Therapeutics (ABEO) Surges: Stock Moves 7.2% Higher
by Zacks Equity Research
Abeona Therapeutics (ABEO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Protalix BioTherapeutics (PLX) Jumps: Stock Rises 9%
by Zacks Equity Research
Protalix BioTherapeutics(PLX) saw its shares rise 9% on the day.
uniQure (QURE) in Focus: Stock Moves 11.9% Higher
by Zacks Equity Research
uniQure (QURE) saw its shares rise nearly 12% on the day.
Exelixis (EXEL) Looks Good: Stock Adds 17.2% in Session
by Zacks Equity Research
Exelixis (EXEL) was a big mover last session, as the company saw its shares rise more than 17% on the day amid huge volumes.
Five Prime Therapeutics, Inc. (FPRX) Jumps: Stock Rises 6.2%
by Zacks Equity Research
Five Prime Therapeutics, Inc. (FPRX) saw its shares rise over 6% on the day.
Athersys (ATHX) in Focus: Stock Moves 7.2% Higher
by Zacks Equity Research
Athersys (ATHX) shares rose more than 7% in the last trading session, amid huge volumes.